Press Releases

Investor Relations

Filter by Year

December 26, 2018

Acer Therapeutics Announces FDA Acceptance of NDA and Priority Review for EDSIVO™ for the Treatment of vEDS

Acer continues progress toward goal of commercializing EDSIVO™   NEWTON, MA – December 26, 2018 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has […]

Read More
November 9, 2018

Acer Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update

Acer continues to progress towards goal of commercializing EDSIVO™   Company appoints VPs of Corporate Development and IT & Database Administrator   NEWTON, MA – November 9, 2018 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet […]

Read More
November 8, 2018

Acer Therapeutics to Present at the Evercore ISI HealthConX Conference

NEWTON, MA – November 8, 2018 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced that Acer’s management team will provide a corporate overview at the Evercore ISI HealthConX Conference, being held November […]

Read More
October 29, 2018

Acer Therapeutics Submits NDA for EDSIVO™ for the Treatment of vEDS

Requests Priority Review NEWTON, MA – October 29, 2018 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug […]

Read More
September 24, 2018

Acer Therapeutics to Present at the 2018 Cantor Global Healthcare Conference

NEWTON, MA – September 24, 2018 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced that Acer’s management team will provide a corporate overview at the 2018 Cantor Global Healthcare Conference, being held […]

Read More
August 18, 2018

Acer Therapeutics to Present at the 20th Annual H.C. Wainwright Conference

NEWTON, MA – August 20, 2018 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced that Acer’s management team will provide a corporate overview at the H.C. Wainwright 20th Annual Global Investment Conference, […]

Read More
August 14, 2018

Acer Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update

Acer Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update   Acer continues to progress towards goal of commercializing EDSIVO™   Company appoints VPs of Medical Affairs and Quality   NEWTON, MA – August 13, 2018 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of […]

Read More
August 3, 2018

Acer Therapeutics Announces Closing of Underwritten Public Offering

NEWTON, MA – August 3, 2018 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced the closing of its previously announced underwritten public offering of 2,555,555 shares of its common stock, including 333,333 […]

Read More
August 1, 2018

Acer Therapeutics Announces Pricing of Underwritten Public Offering

NEWTON, MA – August 1, 2018 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced the pricing of its underwritten public offering of 2,222,222 shares of its common stock at a public offering […]

Read More
May 31, 2018

Acer Therapeutics Announces Underwritten Public Offering

NEWTON, MA – July 31, 2018 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced that it intends to offer and sell shares of its common stock, subject to market and other conditions, […]

Read More
QUICK
NAV